Relevant bibliographies by topics / Malaghan Institute for Medical Research / Journal articles

Journal articles on the topic 'Malaghan Institute for Medical Research'

To see the other types of publications on this topic, follow the link: Malaghan Institute for Medical Research.
Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Malaghan Institute for Medical Research.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Fischer, Kirsten, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, et al. "Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)." Blood 128, no. 22 (December 2, 2016): 2054. http://dx.doi.org/10.1182/blood.v128.22.2054.2054.

Full text
Abstract:
Abstract Introduction The BCL-2 inhibitor venetoclax has yielded promising results in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), both as monotherapy and in combination with rituximab. The CLL14 trial is a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditions. Prior to opening the randomized phase, a run-in phase was performed to assess the tolerability of obinutuzumab and venetoclax in this particular patient population. Here, we report the final results on safety and efficacy of this run-in phase. Method The protocol specified to enroll 12 previously untreated patients with confirmed CLL and with coexisting medical conditions assessed by cumulative illness rating scale (CIRS) total score > 6 and/or estimated creatinine clearance (CrCl) < 70 mL/min requiring treatment according to iwCLL criteria into the run-in phase. All patients received 6 cycles of obinutuzumab and venetoclax followed by 6 additional cycles of venetoclax. Obinutuzumab was administered intravenously with 100 mg on day 1, 900 mg on day 2 (option to deliver 1000 mg on day 1), 1000 mg on day 8 and day 15 of cycle 1 and 1000 mg on day1 for cycles 2-6. A gradual weekly dose ramp-up of venetoclax with 20 mg, 50 mg, 100 mg, 200 mg up to 400 mg was administered starting at day 22 of cycle 1. Risk assessment for tumor lysis syndrome (TLS) based on absolute lymphocyte count and tumor burden was performed before treatment in order to direct prophylactic measures. Study defined stopping criteria for all 12 patients included: one treatment-related death or one grade 4 adverse event related to a clinical tumor lysis syndrome (TLS) despite protocol-specified prophylaxis. Adverse events were graded per the NCI CTCAE v.4 criteria. Final response to treatment including assessment for minimal residual disease (MRD) in peripheral blood by ASO-PCR was assessed per the iwCLL guidelines 3 months after the end of treatment, at month 15. Results Between December 2014 and April 2015, 13 previously untreated patients from Australia, Canada, Germany, New Zealand, United States and Spain were enrolled into the trial. Baseline patient characteristics are summarized in Table 1. The median age was 75 years (range 59 - 88) and 62% of the patients were classified as Binet stage C; 38% of the patients were assessed at medium risk and 62% at high risk for TLS. One patient developed a grade-4 infusion related reaction (IRR) during the first dose of obinutuzumab and was therefore withdrawn from the trial according to the protocol requirements. Eleven of 12 patients completed treatment. One patient discontinued treatment after 6 cycles of obinutuzumab and venetoclax and 2 additional cycles of venetoclax due to patient´s wish. All patients experienced at least one adverse event. The commonest adverse events are summarized in Table 2. No clinical TLS was reported. At month 15, 11 of 12 patients were evaluable for final response assessment. All patients responded to therapy. Complete remissions occurred in 7 of the 12 patients including one complete remission with incomplete bone marrow recovery. Ten of 12 patients had no detectable (<10-4) minimal residual disease (MRD) in peripheral blood and one patient was assessed intermediate (≥10-4<10-2). At month 15, there were no events of disease progression or deaths, translating into an estimated progression-free survival of of 100%. Conclusions The treatment regimen developed for the experimental arm of the CLL14 trial comprising obinutuzumab monotherapy for one cycle followed by venetoclax and obinutuzumab in previously untreated, elderly patients with CLL and coexisting medical conditions appears well tolerated and effective. The target population in this trial consists of elderly patients with clinically meaningful comorbidities in addition to CLL. None of the protocol defined stopping safety criteria for the run-in phase of the trial were met. The treatment induced substantial responses with an unprecedentedly high number of MRD negative responses seen in all but one evaluable patients including those with poor prognostic features. The main phase of the CLL14 trial was opened in August 2015 and completed recruitment in August 2016 after 432 patients had been randomized. Disclosures Fischer: Hoffmann-LaRoche: Other: Travel grants. Al-Sawaf:Gilead: Other: Travel grants. Fink:AbbVie: Other: Travel grants; Mundipharma: Other: Travel grants; Celgene: Other: Travel grants, Research Funding; Hoffmann-LaRoche: Other: Travel grants. Dixon:Roche Products Limited: Employment, Equity Ownership. Bahlo:F. Hoffman-La Roche: Honoraria, Other: Travel grant. Warburton:Roche UK: Employment. Kipps:Gilead: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria. Weinkove:Avalia Immunotherapies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Other: Travel grants; Janssen: Honoraria; Capital & Coast District Health Board: Employment; Malaghan Institute of Medical Research: Employment; Health Research Council of New Zealand: Research Funding; Australasian Leukaemia & Lymphoma Group: Membership on an entity's Board of Directors or advisory committees. Robinson:Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Abbvie: Consultancy; Lundbeck: Consultancy; Gilead: Consultancy. Dreyling:Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau. Opat:Roche: Consultancy, Honoraria, Other: Provision of subsidised drugs, Research Funding. Owen:Pharmacyclics: Research Funding; Janssen: Honoraria; Gilead: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Abbvie: Honoraria; Lundbeck: Honoraria, Research Funding; Novartis: Honoraria. López:Novartis: Consultancy; Abbvie: Consultancy; Merck Sharp & Dohme: Consultancy; Janssen: Consultancy; Roche: Consultancy; Gilead: Consultancy. Humphrey:Genentech, Inc.: Employment. Humerickhouse:AbbVie: Employment. Tausch:Amgen: Other: Travel support; Gilead: Other: Travel support, Speakers Bureau; Celgene: Other: Travel support. Eichhorst:Abbvie: Consultancy; Mundipharma: Consultancy, Research Funding, Speakers Bureau; Roche: Consultancy, Research Funding, Speakers Bureau. Wendtner:Genetech: Consultancy, Honoraria, Research Funding; Hoffmann‐La Roche: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Munipharma: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Janssen‐Cilag: Consultancy, Honoraria, Research Funding; Servier: Consultancy, Honoraria, Research Funding. Langerak:F. Hofmann-LaRoche, Genentech: Research Funding; InVivoScribe Technologies: Patents & Royalties: Royalties are provided to European Network (EuroClonality). Ritgen:Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding. Boettcher:Roche: Research Funding; Abbvie: Research Funding; Celgene: Research Funding. Stilgenbauer:Mundipharma: Consultancy, Honoraria, Other: Travel grants , Research Funding; Novartis: Consultancy, Honoraria, Other: Travel grants , Research Funding; Sanofi: Consultancy, Honoraria, Other: Travel grants , Research Funding; Boehringer Ingelheim: Consultancy, Honoraria, Other: Travel grants , Research Funding; Janssen: Consultancy, Honoraria, Other: Travel grants , Research Funding; Pharmacyclics: Consultancy, Honoraria, Other: Travel grants , Research Funding; Celgene: Consultancy, Honoraria, Other: Travel grants , Research Funding; GSK: Consultancy, Honoraria, Other: Travel grants , Research Funding; Amgen: Consultancy, Honoraria, Other: Travel grants, Research Funding; Genentech: Consultancy, Honoraria, Other: Travel grants , Research Funding; AbbVie: Consultancy, Honoraria, Other: Travel grants, Research Funding; Gilead: Consultancy, Honoraria, Other: Travel grants , Research Funding; Genzyme: Consultancy, Honoraria, Other: Travel grants , Research Funding; Hoffmann-La Roche: Consultancy, Honoraria, Other: Travel grants , Research Funding. Goede:Roche: Consultancy, Honoraria, Other: Travel grant, Research Funding; GlaxoSmithKline: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Mobasher:Genentech, Inc.: Employment. Hallek:Janssen-Cilag: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; Mundipharma: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; F. Hoffmann-LaRoche: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Other: travel support, Research Funding, Speakers Bureau.
APA, Harvard, Vancouver, ISO, and other styles
2

Andrew, R. R. "The Baker Medical Research Institute." Medical Journal of Australia 143, no. 7 (September 1985): 275–76. http://dx.doi.org/10.5694/j.1326-5377.1985.tb123003.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Korner, Paul I. "The Baker Medical Research Institute." Medical Journal of Australia 143, no. 7 (September 1985): 294–99. http://dx.doi.org/10.5694/j.1326-5377.1985.tb123012.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kato, Atsushi. "Kenya Medical Research Institute, KEMRI." Journal of African Studies 1990, no. 36 (1990): 93–94. http://dx.doi.org/10.11619/africa1964.1990.93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Steele, Fintan R. "A new medical research institute." Nature Medicine 2, no. 8 (August 1996): 842. http://dx.doi.org/10.1038/nm0896-842a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Powell, Lawrie W. "The Queensland Institute of Medical Research." Medical Journal of Australia 165, no. 11-12 (December 1996): 645–48. http://dx.doi.org/10.5694/j.1326-5377.1996.tb138675.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shine, John. "The Garvan Institute of Medical Research." Medical Journal of Australia 165, no. 11-12 (December 1996): 649–51. http://dx.doi.org/10.5694/j.1326-5377.1996.tb138676.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kidson, Chev. "The Queensland Institute of Medical Research." Medical Journal of Australia 142, no. 6 (March 1985): 355–59. http://dx.doi.org/10.5694/j.1326-5377.1985.tb113415.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nelson, David S. "The Kolling Institute of Medical Research." Medical Journal of Australia 143, no. 3 (August 1985): 97–101. http://dx.doi.org/10.5694/j.1326-5377.1985.tb122831.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Burnet, Macfarlane. "Medical research: the new Hall Institute." Medical Journal of Australia 143, no. 4 (August 1985): 138. http://dx.doi.org/10.5694/j.1326-5377.1985.tb122868.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

King, Kathleen. "Baker Medical Research Institute International Colloquium." Medical Journal of Australia 146, no. 11 (June 1987): 583–86. http://dx.doi.org/10.5694/j.1326-5377.1987.tb120419.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Krupp, Marcus A., and Allen D. Cooper. "Palo Alto Medical Foundation, Research Institute." Molecular Medicine 3, no. 10 (October 1997): 633–35. http://dx.doi.org/10.1007/bf03401702.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Grakova, E. V., K. V. Kopyeva, A. T. Teplyakov, L. K. Isakov, M. N. Sinkova, and N. I. Tarasov. "Cardiology Research Institute, Tomsk National Research Medical Center." Russian Journal of Cardiology 27, no. 7 (August 9, 2022): 4753. http://dx.doi.org/10.15829/1560-4071-2022-4753.

Full text
Abstract:
Aim. To assess the prognostic role of cardiac biomarkers (galectin-3, soluble ST2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP)) in risk stratification of adverse cardiovascular events (CVEs) in patients with heart failure (HF) after implantation of an automatic implantable cardioverter-defibrillator (AICD) within 12-month follow-up period.Material and methods. The study included 57 patients (men, 41; mean age, 65 (59; 68) years) with coronary artery disease and NYHA class II-III HF with left ventricular ejection fraction of 34 [26; 40]%. All patients were implanted with AICD. Serum levels of NT-proBNP, sST2, and galectin-3 were determined by enzyme immunoassay prior to AICD implantation.Results. It has been established that in order to stratify the risk of unfavorable HF in patients after AICD implantation for 12-month follow-up, all three studied biomarkers can be considered as prognostic factors. Thus, an increase in the level of NT-proBNP ≥1046,6 pg/ml (AUC=0,68; p=0,009), sST2 ≥34,43 ng/ml (AUC=0,78; p<0,0001) and galectin-3 ≥11,6 ng/l (AUC=0,72; p=0,0014) predicts a high risk of adverse CVEs. The combination of sST2 and galectin-3 increased the predictive value of the analysis (AUC=0,84; p<0,0001), while the addition of NTproBNP did not increase the accuracy of risk stratification.Conclusion. The determination of the combination of galectin-3 and sST2 can potentially help identify a group of patients with HF after AICD implantation with a high risk of adverse CVEs for intensification and optimization of treatment.
APA, Harvard, Vancouver, ISO, and other styles
14

Tatarsky, B. A., N. V. Kazennova, R. E. Batalov, and S. V. Popov. "Cardiology Research Institute, Tomsk National Research Medical Center." Russian Journal of Cardiology 25, no. 7 (August 15, 2020): 3388. http://dx.doi.org/10.15829/1560-4071-2020-3388.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Easa, Bassant. "Environmental Assessment of Alexandria Medical Research Institute." Journal of King Abdulaziz University-Meteorology, Environment and Arid Land Agriculture Sciences 20, no. 1 (2009): 83–103. http://dx.doi.org/10.4197/met.20-1.5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Elsoud, MoustafaAbo, and MohamedA Selima. "Endoscopic ampullectomy: a Medical Research Institute experience." Egyptian Journal of Surgery 35, no. 3 (2016): 248. http://dx.doi.org/10.4103/1110-1121.189414.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Spinney, Laura. "London calling for British medical research institute." Nature Medicine 10, no. 8 (July 22, 2004): 762. http://dx.doi.org/10.1038/nm0804-762b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Shanchuk, Tava. "The Hauptman-Woodward Medical Research Institute, Inc." Molecular Medicine 4, no. 11 (November 1998): 693–97. http://dx.doi.org/10.1007/bf03401763.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Anderson, Peter D. "Armed Forces Radiobiology Research Institute (www.afrri.usuhs.mil)." Journal of Pharmacy Practice 23, no. 2 (April 6, 2009): 146. http://dx.doi.org/10.1177/0897190009334327.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Kariuki, James, Joysline Kaburi, Rosemary Musuva, Doris Njomo, Doris Doris, Carolyne Wandera, James Wodera, and Pauline Mwinzi. "Research Dissemination Strategies Used by Kenya Medical Research Institute Scientists." East African Health Research Journal 3, no. 1 (July 30, 2019): 70–78. http://dx.doi.org/10.24248/eahrj.v3i1.601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Easa, Bassant. "Sanitary Conditions of Alexandria Medical Research Institute Hospital." Journal of King Abdulaziz University-Meteorology, Environment and Arid Land Agriculture Sciences 20, no. 1 (2009): 105–20. http://dx.doi.org/10.4197/met.20-1.6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Porterfield, J. S. "The National Institute for Medical Research, Mill Hill." Archives of Virology 140, no. 7 (July 1995): 1329–36. http://dx.doi.org/10.1007/bf01322760.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Kipchirchir, Kebenei Enock. "Research on COVID-19: Story from the Kenya Medical Research Institute." Narrative Inquiry in Bioethics 11, no. 1 (2021): E20—E22. http://dx.doi.org/10.1353/nib.2021.0037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Choynzonov, E. L., Т. Ya Kucherova, I. N. Udintseva, Т. V. Serebrov, V. A. Novikov, А. I. Ryabova, P. V. Surkova, O. V. Cheremisina, and E. A. Sokolova. "Cancer Research Institute, Tomsk National Research Medical Center of the RAS." Head and Neck Tumors (HNT) 9, no. 2 (July 2, 2019): 66–70. http://dx.doi.org/10.17650/2222-1468-2019-9-2-66-70.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Schapper, Catherine C., Terence Dwyer, Geoffrey W. Tregear, MaryAnne Aitken, and Moira A. Clay. "Research performance evaluation: the experience of an independent medical research institute." Australian Health Review 36, no. 2 (2012): 218. http://dx.doi.org/10.1071/ah11057.

Full text
Abstract:
Background. Evaluation of the social and economic outcomes of health research funding is an area of intense interest and debate. Typically, approaches have sought to assess the impact of research funding by medical charities or regional government bodies. Independent research institutes have a similar need for accountability in investment decisions but have different objectives and funding, thus the existing approaches are not appropriate. Methods. An evaluation methodology using eight indicators was developed to assess research performance across three broad categories: knowledge creation; inputs to research; and commercial, clinical and public health outcomes. The evaluation approach was designed to provide a balanced assessment across laboratory, clinical and public health research. Results and discussion. With a diverse research agenda supported by a large number of researchers, the Research Performance Evaluation process at the Murdoch Childrens Research Institute has, by necessity, been iterative and responsive to the needs of the Institute and its staff. Since its inception 5 years ago, data collection systems have been refined, the methodology has been adjusted to capture appropriate data, staff awareness and participation has increased, and issues regarding the methodology and scoring have been resolved. Conclusions. The Research Performance Evaluation methodology described here provides a fair and transparent means of disbursing internal funding. It is also a powerful tool for evaluating the Institute’s progress towards achieving its strategic goals, and is therefore a key driver for research excellence. What is known about the topic? Increasingly, research funders are seeking to evaluate the impact and outcomes of research spending in order to inform policy decisions and guide research funding expenditure. However, in most instances, research evaluation activities are not undertaken by the organisation conducting the actual research and may not meet their practical needs. What does this paper add? The paper outlines a research performance evaluation methodology specifically tailored to the needs of the medical research institute conducting the research being evaluated, as a way of evaluating research performance to drive strategic goals and disburse internal funds. What are the implications for practitioners? This paper provides a clear approach to internal research evaluation using a process that meets the needs of the organisation actually conducting the research, and provides institutional data for strategic planning activities.
APA, Harvard, Vancouver, ISO, and other styles
26

Bosch, Xavier. "Allegations fly over fate of UK medical research institute." Nature Medicine 11, no. 1 (January 2005): 4. http://dx.doi.org/10.1038/nm0105-4b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

O'ROURKE, M. F. "A DIAMOND ANNIVERSARY. THE BAKER MEDICAL RESEARCH INSTITUTE, MELBOURNE." Australian and New Zealand Journal of Medicine 17, no. 2 (April 1987): 185–86. http://dx.doi.org/10.1111/j.1445-5994.1987.tb00035.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Lang, Leslie H. "Howard Hughes Medical Institute seeks 50 new research fellows." Gastroenterology 127, no. 1 (July 2004): 5. http://dx.doi.org/10.1053/j.gastro.2004.05.058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Nossal, G. J. V. "The Walter and Eliza Hall Institute of Medical Research." Molecular Medicine 2, no. 2 (March 1996): 165–68. http://dx.doi.org/10.1007/bf03401612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Гинтер, Е. К., and Л. М. Константинова. "Research Centre for Medical Genetics: Short History." Nauchno-prakticheskii zhurnal «Medicinskaia genetika», no. 12() (December 20, 2019): 34–49. http://dx.doi.org/10.25557/2073-7998.2019.12.34-49.

Full text
Abstract:
Медико-генетический научный центр (ФГБНУ МГНЦ) сформировался на базе Института медицинской генетики (ИМГ) АМН СССР. В структуре Института с самого начала была заложена организация научных отделов, в которых разрабатывались бы основные для того времени исследовательские направления: популяционная генетика, клиническая генетика, цитогенетика и биохимическая генетика. Самые заметные изменения в структуре Института и тематике научных исследований произошли в связи с реорганизацией ИМГ АМН СССР во Всесоюзный научный медико-генетический центр в 1989 г. В настоящее время сотрудники ФГБНУ МГНЦ проводят исследования по всем основным направлениям медицинской генетики, разрабатывают уникальные методы эффективной диагностики и новые методы лечения наследственных болезней. The Research Centre for Medical Genetics (FSBI RCMG) was established based on the Institute of Medical Genetics (IMG) of the USSR Academy of Medical Science. From the very beginning, the structure of the Institute provided for the research departments that would develop the main research areas of that time: population genetics, clinical genetics, cytogenetics and biochemical genetics. The restructuring of the IMG into the All-Union Research Centre for Medical Genetics led to the most noticeable changes in the Institute structure. Research in all major areas of medical genetics, the development of unique methods for the effective diagnosis and treatment of hereditary diseases are currently being carried out at the Center.
APA, Harvard, Vancouver, ISO, and other styles
31

MARCISZ, Jarosław, Józef PADUCH, and Adam ZIELIŃSKI. "ŁUKASIEWICZ RESEARCH NETWORK – INSTITUTE FOR FERROUS METALLURGY – CURRENT AND FUTURE RESEARCH ACTIVITIES." Journal of Metallic Materials, no. 3-4 (December 30, 2022): 2–13. http://dx.doi.org/10.32730/imz.2657-747.22.3-4.1.

Full text
Abstract:
At the beginning of 2023, Łukasiewicz Research Network – Institute for Ferrous Metallurgy (Łukasiewicz – IMŻ) begins its activity in the structure of a new institute under the name of Łukasiewicz Research Network – Upper Silesian Institute of Technology, after consolidation with Łukasiewicz – Institute of Welding and Łukasiewicz – Institute of Electrical Drives and Machines KOMEL. On the eve of this change, this study presents the research achievements of Łukasiewicz – IMŻ in 2022 and the topics planned to be undertaken in 2023. It takes into account projects financed from the national and EU budget for science, as well as the significant involvement of the Institute in the implementation of applied projects that contribute to increasing the innovativeness of the domestic industry, including the energy and defence sectors. Attention was paid to the dynamically developing new hydrogen technologies in metallurgy, additive technologies and high-temperature material characteristics, important for the aerospace industry. At the same time, we would like to announce that the current issue of “Journal of Metallic Materials” is the last issue of our quarterly, publishing original research results in the field of metallurgy, materials engineering, chemistry, environmental protection and management in the iron and steel industry. Its traditions date back to 1949, when the first issue of the journal was published under the title “Prace Badawcze Głównego Instytutu Metalurgii i Odlewnictwa (Research Works of the Central Institute of Metallurgy and Casting)”. In 1976-2018, the quarterly was published under the title “Prace Instytutu Metalurgii Żelaza (Works of the Institute for Ferrous Metallurgy)”. The title changed to the current one in 2019. On behalf of the entire editorial team, we would like to thank all readers and authors of articles and reviewers for their cooperation. The establishment of the new Institute will certainly create conditions for the continuation of publishing activities in a broader substantive scope.
APA, Harvard, Vancouver, ISO, and other styles
32

Sagadatova, N. M., G. K. Zaynutdinova, and M. S. Absalyamov. "Postgraduate Education in Ufa Eye Research Institute." POINT OF VIEW. EAST – WEST, no. 2 (May 31, 2021): 28–31. http://dx.doi.org/10.25276/2410-1257-2021-2-28-31.

Full text
Abstract:
The article presents the results of the work of the Scientific and Educational department of the Ufa Eye Research Institute of the Academy of Sciences of the Republic of Bashkortostan for 2016-2020. The activities of the Scientific and Educational department allowed us to create a system of training qualified medical personnel, improve the quality of postgraduate professional education of ophthalmologists, which will contribute to improving the efficiency of using the achievements of modern science and technology in everyday medical practice when providing medical care to the population. Key words: Ufa Eye Research Institute, postgraduate education, Scientific and Educational department, results of work, WETLAB.
APA, Harvard, Vancouver, ISO, and other styles
33

Chi, Je Geun. "Prospectives of Research Institute of Healthcare Policy, Korean Medical Association." Journal of the Korean Medical Association 46, no. 3 (2003): 172. http://dx.doi.org/10.5124/jkma.2003.46.3.172.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Abo Elsoud, MoustafaR, and MohamedG Soror. "Discharging patients after colorectal surgery: a Medical Research Institute experience." Egyptian Journal of Surgery 34, no. 4 (2015): 264. http://dx.doi.org/10.4103/1110-1121.167389.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Rusch, Harold P. "The Role of a Research Institute in a Medical School." Academic Medicine 79, no. 10 (October 2004): 980. http://dx.doi.org/10.1097/00001888-200410000-00018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Nossal, G. J. V. "Places: The Walter and Eliza Hall Institute of Medical Research." BioEssays 2, no. 4 (April 1985): 181–83. http://dx.doi.org/10.1002/bies.950020411.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Diamond, Betty, and Frances Santiago-Schwarz. "Introduction to immunology at Feinstein Institute for Medical Research (FIMR)." Immunologic Research 63, no. 1-3 (October 16, 2015): 1–2. http://dx.doi.org/10.1007/s12026-015-8721-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Mullins, C. Daniel. "The advent of a Patient-Centered Outcomes Research Institute." Clinical Therapeutics 32, no. 4 (April 2010): 716. http://dx.doi.org/10.1016/j.clinthera.2010.04.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Pugliese, Gina. "New AIDS Research Institute Opens in San Francisco." Infection Control & Hospital Epidemiology 14, no. 6 (June 1993): 351. http://dx.doi.org/10.1017/s0195941700011991.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Kepinska-Kasprzak, Malgorzata, and Piotr Struzik. "Agrometeorological service provided by Institute of Meteorology and Water Management – National Research Institute." Biological Rhythm Research 50, no. 2 (September 13, 2018): 327–34. http://dx.doi.org/10.1080/09291016.2018.1518874.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Nambiar, Archana, and Somasundaram Subramaniam. "Forum for Interdisciplinary Research in Medical Science & Technology." Physician 6, no. 3 (February 1, 2021): 1–53. http://dx.doi.org/10.38192/1.6.3.firmst20.

Full text
Abstract:
Abstracts presented at the FIRMST 2020 Conference | 4-5 August 2020 | Moscow Curated and peer-reviewed by Professor JS Bamrah, Professor Soumit Dasgupta & Dr Neeraj Bhala for Bapio Institute for Health Research, Bedford, UK
APA, Harvard, Vancouver, ISO, and other styles
42

Šarić, Marko. "Andrija Štampar and the Institute for Medical Research and Occupational Health." Archives of Industrial Hygiene and Toxicology 60, no. 1 (March 1, 2009): 1–6. http://dx.doi.org/10.2478/10004-1254-60-2009-1914.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

MITSUFUJI, Hidehiko. "The Dual Missions of Ehime Traditional Medical Institute of Medical Care and Scientific Research." Zen Nihon Shinkyu Gakkai zasshi (Journal of the Japan Society of Acupuncture and Moxibustion) 53, no. 5 (2003): 578–87. http://dx.doi.org/10.3777/jjsam.53.578.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Blumstein, Z. I. "Hydrochemical research." Kazan medical journal 32, no. 8-9 (October 4, 2021): 745–55. http://dx.doi.org/10.17816/kazmj81242.

Full text
Abstract:
To carry out the determination of hydrogen sulfide, a special laboratory was deployed in the village of Bakirovo, mainly organized by the laboratory of biological chemistry of the Medical Research Institute [1] with the full assistance of TNKZdrav.
APA, Harvard, Vancouver, ISO, and other styles
45

Kuznetsova, E. G. "V.P. Aksenov in Kazan medical institute." Kazan medical journal 96, no. 5 (October 15, 2015): 883–86. http://dx.doi.org/10.17750/kmj2015-883.

Full text
Abstract:
Aim. To explore the archives, to analyze the biographical data and to uncover one of the life periods of the Russian writer Vasily Pavlovich Aksenov (1950-1954), when he studied at the medical-prophylactic faculty of Kazan State Medical Institute. Methods. Biographical research methods (writer’s biographic data, the memories of relatives, friends, colleagues, and various records, interviews, etc.), local history (materials of Kazan period of the writer’s life), as well as historical and literary (all information about V.P. Aksenov fit into the context of country’s historical and literary situation) were used. Results. The named period of writer’s life was studied in detail. Materials stored in the archives of the Kazan State Medical University, as well as biographical data of V.P. Aksenov, memories and text works that mention the Kazan period of writer’s student life were analyzed. Time of youth, open-mindedness, a desire to live are found side by side with mediocrity, fear of tomorrow and unknown. Harassment, shadowing, exile - all this «tempered and fostered» Aksenov. Friends, family, mainly the mother helped him to fight for his rights, to move on. Conclusion. Time spent by V.P. Aksenov on the Volga bank, attending the Kazan Medical Institute largely determined his future career path, formed a worldview and sense of self as a person and a writer; Kazan story of student Aksenov is one of many examples of man’s destiny in the transitional period of life of the state.
APA, Harvard, Vancouver, ISO, and other styles
46

Nossal, Gustav J. V. "The Walter and Eliza Hall Institute of Medical Research: 1915–1985." Medical Journal of Australia 143, no. 4 (August 1985): 153–57. http://dx.doi.org/10.5694/j.1326-5377.1985.tb122875.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Gewin, Virginia. "Daniel Kelly, scientific director, Burnham Institute for Medical Research, Orlando, Florida." Nature 452, no. 7184 (March 2008): 250. http://dx.doi.org/10.1038/nj7184-250a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Cumming, Gordon. "Midhurst Medical Research Institute, Midhurst, West Sussex GU29 OBL, United Kingdom." Clinical Physiology 5, s3 (May 1985): 33–37. http://dx.doi.org/10.1111/j.1475-097x.1985.tb00599.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Angus, James A. "SYMBIOTIC RELATIONSHIP BETWEEN A RESEARCH INSTITUTE AND A PHARMACEUTICAL COMPANY: THE BAKER INSTITUTE/GLAXO AUSTRALIA STORY." Clinical and Experimental Pharmacology and Physiology 19, no. 1 (January 1992): 67–71. http://dx.doi.org/10.1111/j.1440-1681.1992.tb00400.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Nunn, Tony. "The National Institute for Health Research Medicines for Children Research Network†." Pediatric Drugs 11, no. 1 (2009): 14–15. http://dx.doi.org/10.2165/0148581-200911010-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Malaghan Institute for Medical Research' for other source types:
Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography